Kwak, Mi Kyung Hur, Keun Yu, Ji Eun Han, Tae Su Yanagihara, Kazuyoshi Kim, Woo Ho Lee, Sun Mi Song, Soo-Chang Yang, Han-Kwang 2024-01-20T19:04:48Z 2024-01-20T19:04:48Z 2021-09-02 2010-06 0167-6997 https://pubs.kist.re.kr/handle/201004/131426 Current systemic chemotherapy in the treatment of solid tumors inevitably induces various systemic adverse effects. Locally injected chemotherapy is expected to overcome this limitation of systemic therapy. We evaluated by luminescence imaging the effects of chemotherapy administered locally by means of a biodegradable thermosensitive hydrogel polymer. The human gastric cancer cell line HSC44Luc was used for tumor induction, and it was confirmed to be sensitive to doxorubicin by MTT assay. Cells were injected subcutaneously into Balb/c-nude mice. When the mean volume of tumor reached 400 mm(3), we divided the mice into 6 groups (5 per group) according to treatment: 1) control (intratumor injection of PBS), 2) systemic injection of doxorubicin, 3) intratumor injection of polymer gel, 4) intratumor injection of polymer gel physically mixed with a low dose of doxorubicin, 5) intratumor injection of polymer gel physically mixed with a high dose of doxorubicin, 6) intratumor injection of conjugated polymer gel with doxorubicin. Body weight and tumor volume were measured every 2 or 3 days for 30 days after treatment. One mouse in each group was sacrificed for histopathologic examination every week. Reductions in body weight were not significantly different among groups. The relative rate of tumor growth was 774% in Group 1, 267% in Group 2, 813% in Group 3, -186% in Group 4, and 155% in Group 6, respectively. Thus the relative rate of tumor growth in the groups treated with polymer gel mixed with doxorubicin and the groups treated with conjugated polymer gel with doxorubicin were lower than that in the control group. Locally injectable chemotherapy using a thermosensitive hydrogel polymer with doxorubicin can suppress tumor growth effectively without severe systemic toxicity. English SPRINGER DRUG-DELIVERY CONTROLLED-RELEASE NANOPARTICLES PACLITAXEL DESIGN Suppression of in vivo tumor growth by using a biodegradable thermosensitive hydrogel polymer containing chemotherapeutic agent Article 10.1007/s10637-009-9253-5 1 INVESTIGATIONAL NEW DRUGS, v.28, no.3, pp.284 - 290 INVESTIGATIONAL NEW DRUGS 28 3 284 290 scie scopus 000276430200010 2-s2.0-77952238688 Oncology Pharmacology & Pharmacy Oncology Pharmacology & Pharmacy Article DRUG-DELIVERY CONTROLLED-RELEASE NANOPARTICLES PACLITAXEL DESIGN Hydrogel polymer Cancer growth Bioluminescence imaging